Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1842
Title: SUBA-itraconazole for primary antifungal prophylaxis after allogeneic hematopoietic cell transplantation.
Author: Lindsay, J.
Othman, J.
Kong, Y.
Yip, A.
Van Hal, S.
Bryant, C.
Gibson, J.
Kerridge, I.
Fay, K.
Stevenson, W.
Arthur, C.
Chen, S.
Kong, David C. M.
Greenwood, M.
Pergam, S.
Liu, C.
Slavin, M.
Issue Date: 2021
Publication Title: Open Forum Infectious Diseases
Volume: 8
Issue: 11
Abstract: Background: Itraconazole (ITZ) is an effective agent when used as primary invasive fungal disease (IFD) prophylaxis, but is limited by drug tolerability and variability in serum concentrations. A new formulation, SUBA-itraconazole (for “super bioavailability”; S-ITZ), addresses the limitations of conventional ITZ formulations. Methods: We conducted a retrospective cohort study at 2 Australian centers to evaluate the safety, tolerability, and effectiveness of S-ITZ as primary antifungal prophylaxis in hematopoietic cell transplant (HCT) recipients without grade II–IV acute graft-vs-host disease, from day 1 until approximately day 100 (cohort A) or day 1 until neutrophil engraftment (cohort B). A total of 204 patients and 1410 trough plasma ITZ concentrations were assessed. Results: The incidence of breakthrough proven/probable IFD at day 180 was 1.0% (95% confidence interval [CI], .2%–3.2%), with 1.6% in cohort A and 0% in cohort B, and overall fungal-free survival of proven/probable IFD was 82.9% (95% CI, 76.8%–87.4%). Preengraftment early permanent S-ITZ discontinuation was 3.4% overall, with no significant difference between cohorts. No patients required cessation due to gastrointestinal intolerance attributed to S-ITZ. The geometric mean trough plasma ITZ concentration was 1130ng/mL (interquartile range, 566–1801ng/mL; coefficient of variation, 56.57%) and the median time to achieve therapeutic levels was 10 days. Conclusions: S-ITZ is a safe and well-tolerated oral formulation and is a novel alternative for primary IFD prophylaxis after HCT.
URI: http://hdl.handle.net/11054/1842
DOI: https://doi.org/10.1093/ofid/ofab502
Internal ID Number: 01867
Health Subject: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT)
ANTIFUNGAL PROPHYLAXIS
ITRACONAZOLE
HCT
S-ITZ
SUBA
ITRACONAZOLE
Type: Journal Article
Article
Appears in Collections:Research Output

Files in This Item:
File Description SizeFormat  
Open Forum Infectious Disease - uploaded with permission.pdfOpen Forum Infectious Disease - uploaded with permission705 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.